2016 Annual Meeting of the American Association for the Study of Liver Diseases*

November 11-15, 2016; Boston, Massachusetts
Examine Capsule Summaries, download slides, and review analysis by expert faculty on key studies from Boston 2016.



Regimen highly effective in difficult-to-treat populations, including cirrhotics and those with genotype 3 HCV infection.

Released: November 17, 2016

For patients with GT3 HCV infection, high SVR12 rates with once-daily treatment regardless of cirrhosis, treatment experience, or treatment duration.

Released: November 22, 2016

Glecaprevir/pibrentasvir for 12 or 16 weeks proved effective in cirrhotic patients with genotype 3 HCV infection, including those with treatment experience.

Released: November 16, 2016

Baseline NS3 and NS5A RAVs did not affect achievement of SVR8 with MK-3682/grazoprevir/ruzasvir with or without RBV.

Released: November 18, 2016

High SVR12 rates with once-daily, ribavirin-free treatment in cirrhotics and those with baseline resistance associated substitutions.

Released: November 18, 2016

Glecaprevir/pibrentasvir similarly effective in HCV/HIV-coinfected patients and patients previously treated with sofosbuvir.

Released: November 18, 2016

Triple-drug regimen effective regardless of treatment experience.

Released: November 17, 2016

In this phase IIb trial, greater benefits observed in patients with greater disease activity treated with the CCR2/5 blocker.

Released: November 23, 2016

Glecaprevir/pibrentasvir was effective in both treatment-naive and treatment experienced patients with or without compensated cirrhosis.

Released: November 18, 2016

In a mixed population of cirrhotics and noncirrhotics, higher relapse rate in patients with genotype 1a HCV infection appeared to drive failure of 8-week SOF/VEL/voxilaprevir to meet criteria for noninferiority to 12-week SOF/VEL.

Released: November 18, 2016

Treatment safe and tolerable with no discontinuations for study drug-related adverse events.

Released: November 17, 2016

Significant clinical complications including death, decompensation, and liver transplantation observed with HBV reactivation in setting of HCV DAA therapy.

Released: November 16, 2016

Selonsertib improved liver stiffness in patients with NASH and F2/F3 fibrosis, but had no effect on NAFLD Activity Score.

Released: November 18, 2016
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)

Educational grant provided by:
Merck & Co., Inc.
Gilead Sciences

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.